Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 1 ( January, 2022 ) > List of Articles

Original Article

Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study

Dhruv Talwar, Nitin Raisinghani, Sparsh Madaan, Vidyashree Hulkoti, Annadatha Akhilesh, Shivam Khanna, Divit Shah, Shubham Nimkar

Keywords : COVID-19, High-resolution computed tomography score, Interleukin 6, Neutrophil:lymphocyte ratio

Citation Information : Talwar D, Raisinghani N, Madaan S, Hulkoti V, Akhilesh A, Khanna S, Shah D, Nimkar S. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study. Indian J Crit Care Med 2022; 26 (1):39-42.

DOI: 10.5005/jp-journals-10071-24075

License: CC BY-NC 4.0

Published Online: 17-01-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Interleukin 6 (IL-6) encoded by the gene coded as IL 6 acts as a proinflammatory cytokine as well as an anti-inflammatory myokine. It is postulated that IL 6 is associated directly with the severity of coronavirus disease-2019 (COVID-19). Another domain that is thought to predict the severity of COVID-19 is the neutrophil:lymphocyte (N:L) ratio; a higher N:L ratio is postulated to be related to more severe outcomes. Thus, the present study was aimed to establish a correlation of COVID-19 with IL-6 in terms of clinical outcomes. We had also tried to find the relationship between IL-6 and N:L ratio and high-resolution computed tomography (HRCT) score. Methods: We have conducted a cross-sectional study of 200 patients who were admitted to the intensive care unit (ICU) with reverse transcriptase-polymerase chain reaction (RT-PCR) positive for COVID-19 from January to May 2021. Serum IL-6, N:L ratio, and HRCT chest were conducted on admission. Result: Out of 200 patients who were admitted to the ICU with COVID-19, while the IL-6 was higher in patients with increased N:L ratio and HRCT score, the association of IL-6 with clinical outcomes in terms of discharged and expired was found to be statistically not significant. Conclusion: Serum IL-6 was found not to be a potent marker for clinical outcomes in ICU patients in terms of death vs survived. However, the IL-6 levels on admission can be correlated with the computed tomography (CT) severity scores as well as N:L ratio of patients admitted to an ICU.

  1. Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med 2020;18(1):406. DOI: 10.1186/s12967-020-02571-x.
  2. Grifoni E, Valoriani A, Cei F, Lamanna R, Gelli AMG, Ciambotti B, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect 2020;81(3):452–482. DOI: 10.1016/j.jinf.2020.06.008.
  3. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: a systematic review and meta-analysis. Rev Med Virol 2020;30(6):e2141. DOI: 10.1002/rmv.2141.
  4. Montesarchio V, Parrella R, Iommelli C, Bianco A, Manzillo E, Fraganza F, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer 2020;8(2):e001089. DOI: 10.1136/jitc-2020-001089.
  5. Conrozier T, Lohse A, Balblanc JC, Dussert P, Royer PY, Bossert M, et al. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease-2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol 2020;38(4): 742–747. PMID: 32573419.
  6. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol 2020;92(11):2283–2285. DOI: 10.1002/jmv.25948.
  7. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 2019;15(8):813–822. DOI: 10.1080/1744666X.2019.1629904.
  8. Zhao D, Yao F, Wang L, Zheng L, Gao Y, Ye J, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020;71(15):756–761. DOI: 10.1093/cid/ciaa247.
  9. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019;4(4):e123158. DOI: 10.1172/jci.insight.123158.
  10. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1091. DOI: 10.1136/bmj.m1091.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.